initi buy pt turn
ship acceler growth
zimmer biomet global leader musculoskelet space design
manufactur sell large-joint hip/kne sport medicin extrem
trauma spine craniomaxillofaci thorac dental procedur
invest stanc new manag took helm zimmer biomet
compani implement two-year turnaround plan reinvigor
growth turn corner two-year mark growth
slowli sure recov model low-singl digit revenu growth
acceler current level zimmer biomet begin
return low-singl eventu mid-singl digit growth expect focu
shift bottom-lin see sever lever pull drive
earn growth margin expans
turnaround stori materi histor headwind relat
manufactur constraint suppli level recent year impact
compani abil achiev low-single-digit revenu growth quarter
opinion model call growth give
credit signific invest compani made recent year
turnaround busi manag portfolio organ
revenu growth acceler current level expect growth
driven sustain recoveri larg joint busi like augment
newly-launch robot system see higher contribut
segment busi higher-growth end market addit
believ manag may choos incorpor inorgan deal time
compani achiev low-singl digit revenu growth think
translat strong earn growth appear street model effect
oper leverag next year modest improv think
enough lever pull compani hit beat
earn project year follow
valuat risk appli price-to-earnings multipl ep estim
deriv pt risk includ unexpect slowdown core
end market competit core end market and/or price pressur
product launch includ rosa robot system underwhelm
versu expect suppli disrupt remedi progress
execut issu impact zimmer biomet abil regain market share
tr target
initi buy pt
page
appli price-to-earnings multipl discount
median med-tech larg cap peer group
ep estim deriv
pt buy-rat share
unexpect slowdown core end market includ larg joint
neg impact compani target weighted-averag market
growth rate revenu growth competit core end market
either larg establish healthcar compani new smaller
competit entrant differenti technolog impact abil
regain market share price pressur product launch
includ rosa robot system gain traction market
underwhelm versu expect suppli disrupt
remedi progress execut issu impact zimmer
biomet abil regain market share achiev
page
scenariobear casestrhbul flat top-lin growth modest declin oper margin price-to-earnings multipl contract lsd top-lin growth assum oper margin essenti flat modest improv price-to-earnings multipl expans still discount peer includ sykassum lsd top-lin growth gm expans price-to-earnings multipl expans in-lin peer group discount sykupsid vs current inc
zimmer biomet global leader musculoskelet space billion world-wide
revenu zimmer found acquir bristol-my spun-off
individu publicly-trad compani earli zimmer announc would acquir biomet
billion emerg one largest orthoped compani world
major revenu come sale product sold large-joint hip/kne
procedur though compani also design manufactur sell comprehens list product
sport medicin extrem trauma spine craniomaxillofaci thorac dental procedur
compani offer broad orthoped offer strong brand recognit allow zimmer act
partner hospit time vendor consolid
addit zimmer biomet global presenc diversifi revenu base
revenu come intern market compani oper countri world-wide
sell product countri
compani file strh estim
compani bucket revenu six categori includ
knee revenu
hip revenu
 revenu
spine craniomaxillofaci thorac revenu
dental revenu
less revenu
note set includ product sold surgic sport medicin extrem foot ankl
page
presid ceo
zimmer
spun-off
bryan hanson appoint
global launch persona
launch vanguard
robot
fda clearanc
biomet
issu suppli
dental larg
page
zimmer biomet matter stock item compani return mid-single-digit revenu growth
strh thought think
zimmer company-specif challeng recent year due part dis-synergi disrupt encount
merger biomet manufactur issu exasper qualiti issu impact compani abil produc
adequ suppli disrupt associ merger fairli straightforward combin two orthoped giant result
sell dis-synergi simpli weigh perform bit longer anticip compani suppli issu requir bit
zimmer biomet first merg becam clear combin entiti could manufactur adequ product fulfil demand
conting plan place ensur suppli could meet demand sale repres unabl fulfil order
led perpetu back order custom issu late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu observ uncommon med-tech cite condit may constitut
violat food drug cosmet fd act relat act compani encourag address respond
observ april zimmer receiv relat north campu facil respond fda august
zimmer receiv warn letter fda cite outstand qualiti issu facil compani sought
address issu manufactur qualiti remedi effort suppli product neg impact addit
compani need priorit resolut manufactur issu simpli took time invest away prioriti
believ compani abl grow least line weighted-averag market growth rate estim next coupl
year today revenu tie hip knee market gener grow low-singl digit rang year
compani invest robot platform goal abl reviv larg joint busi invest area
higher growth potenti set end market growth rate mid upper singl digit
page
market sizemarket sharemarket growth compani present octob market size share estimateszimm biomet zimmer biomet hold inc
zimmer biomet matter stock item dont robot system
strh thought ye consensu expect knee growth still seem low
zimmer biomet lose market share knee busi recent year part
compani impact before-ment suppli constraint relat
qualiti remedi effort howev also believ zimmer innov engin
slow time frankli focu requir elsewher
time period competitor name abl launch new
product taken market share histor fairli sticki market
importantli compani launch mako total knee applic earli
year zimmer biomet acquir rosa robot platform origin
applic rosa spine compani develop platform offer
total knee applic compani show system proto-typ american
academi orthoped surgeon aao annual meet receiv clearanc
rosa knee system januari
rosa knee featur pre-op plan tool real-tim intraop data
soft-tissu bone anatomi design improv bone cut accuraci rang
motion gap analysi potenti improv flexion restor natur joint
earli launch process compani place hand system
thu far seem plenti runway zimmer biomet grow robot presenc
exist zimmer account oppos fight robot share competit
account addit estim procedur done robot today
therefor still tremend opportun zimmer success
grow market expect zimmer price system rang
fairli wide rang well see launch progress ultim
think compani benefit implant pull-through surgeon begin grow
util system
zimmer biomet revenu come knee busi therefor
import compani regain least share-neutr posit certainli think
robot launch help point time consensu model knee
growth next year
page
zimmer biomet matter stock item what earn potenti next sever year
strh thought think earn growth acceler next sever year
street expect zimmer biomet earn target essenti stagnant last month sit
next year impli earn growth next year consensu sit consensu
major earn growth near-term like driven financi leverag rather oper leverag point
consensu oper margin estim essenti flat improv declin weve seen recent histori call
moder improv
expect gross margin soft potenti year-over-year due higher cost good sold tie current ineffici
improv inventori turn system though consensu alreadi model case think dynam well understood point
price pressur consist estim basi point headwind gross margin though price headwind noth new orthoped
gener off-set mix improv
think consensu expect set appropri think target unrealist given
compani deliv oper margin low rang histor begin show leverag particularli
compani acceler revenu growth rate
compani report factset
page
factset gross oper margin estimateszimm biomet zimmer biomet hold inc
presid ceo
evp cfo
bryan hanson serv presid ceo
zimmer biomet sinc decemb mr
hanson held sever execut posit
career strong track record
lead grow global medic devic
prior zimmer biomet mr hanson serv
member execut committe execut
vice presid group presid
therapi group busi mr
hanson oversaw provid strateg direct
billion invas therapi busi
suketu upadhyay newest member
zimmer biomet execut team join
compani execut vice presid
cfo juli
prior join zimmer biomet mr upadhyay
spent year bristol-my squibb
recent serv svp global financi
oper mr upadhyay held sever
financi leadership role year
career healthcar industri
coleman lannum serv senior vice
presid investor relat zimmer biomet
sinc march mr lannum respons
consult execut manag
sharehold investor commun
mr lannum year investor
relat experi healthcar
industri recent serv svp
investor strategi investor relat
offic mallinckrodt pharmaceut
svp global qualiti regulatori
group presid global busi
svp global oper logist
april
mr tripp serv svp global
oper logist sinc april
prior join mr tripp serv svp
manufactur
cardin work vice-president
oper patient monitor
recoveri busi mr tripp retir
 navi navi reserv year
servic
david kunz serv svp global qualiti
regulatori affair zimmer biomet sinc
april compani sinc
mr kunz also chair compani qualiti
mr kunz join zimmer biomet origin vice-president
regulatori affair qualiti assur
spine divis held posit
time transit role svp global
qualiti regulatori affair prior zimmer mr
kunz serv vice presid qualiti
ivan torno serv group presid
orthoped zimmer biomet sinc
novemb current role mr torno
respons compani orthoped
group includ joint sport
extrem trauma busi well
america region
prior zimmer mr torno serv
variou global role fortun
compani recent world-wide
presid global urolog medic
critic divis becton dickinson
incent tie adjust ep consolid adjust oper profit consolid
constant currenc revenu consolid free cash flow execut
annual perform bonu determin
incent tie region adjust oper profit region constant currenc revenu
region free cash flow apac emea execut
prsu tie constant currenc revenu growth rel total sharehold return
compar index constitu compani
execut chairman board hospira
ceo prior hospira
mr begley spent nearli year abbott
held senior leadership posit
retir includ presid
ceo consum prior ms
bernard held leadership role sever global
current presid ceo inc
join found gkb global
serv ceo unitedhealthcar
current ceo resm inc risen
variou leadership role sinc
chairman wellpoint inc inc
ceo
svp cfo posit
retir
ceo presid board member assertio
recent ms hilado serv evp cfo
allergan retir
svp presid asia pacif emea em
thermo fisher scientif sinc rise
variou leadership posit within
compani sinc join
mr michelson current senior advisori
kkr manag sinc
member kkr manag llc prior
page
compani report strh estim
page
million except per share interest expens inc analysisgross inc
compani report strh estim
page
term incom current plant equip asset incom sharehold equityaccount tax current term bristol-mey current invest zimmer biometminor equiti common paid comp incom sharehold liabil sharehold zimmer biomet hold inc
compani report strh estim
page
 payment tax benefit stock opt payabl accru asset oper sale net invest borrow paid increas decreas due transact tax benefit stock option common non-control financ exchang rate chang decreas cash equiv begin equiv end zimmer biomet hold inc
zimmer biomet global leader musculoskelet space design manufactur sell
large-joint hip/kne sport medicin extrem trauma spine craniomaxillofaci thorac
new manag took helm compani implement two-year
turnaround plan reinvigor growth turn corner two-year mark growth
slowli sure recov model low-singl digit revenu growth
acceler current level zimmer biomet begin return low-singl eventu mid-
singl digit growth expect focu shift bottom-lin see sever lever pull
drive earn growth margin expans rate share buy
valuat risk
appli price-to-earnings multipl discount median med-tech larg cap peer group
ep estim deriv pt risk valuat target price
includ unexpect slowdown core end market includ larg joint neg impact
compani target weighted-averag market growth rate revenu growth competit core
end market either larg establish healthcar compani new smaller competit entrant
differenti technolog impact abil regain market share price pressur product
launch includ rosa robot system gain traction market underwhelm
versu expect suppli disrupt remedi progress execut issu impact
zimmer biomet abil regain market share achiev sustain msd organ growth
kaila krum herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
